The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

"If artificial intelligence is going to be impactful, it needs to be better than the human eye," said the lead researcher.